While training wasn't exactly instinctive, Monaco quickly found that by strengthening his body, he could at least begin to ...

Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced significant progress in its nomlabofusp program for Friedreich’s ...

Kyle Bryant was diagnosed with Friedreich's Ataxia, or FA, at 17 years old. Friedreich's Ataxia is a a rare neuromuscular disease that affects 1 in 50,000 people. Over the last ...

Leerink lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $18 from $19 and keeps an Outperform rating on the shares. The firm ...

Citi says a share overhang has been removed after Larimar Therapeutics (LRMR) announced it has received FDA alignment on an accelerated ...